SPR Therapeutics has announced the presentation of four featured abstracts at the 2025 North American Neuromodulation Society (NANS) annual meeting (30 January–1 February, Orlando, USA). All the abstracts contained recent clinical data and insights highlighting the utility of the Sprint peripheral nerve stimulation (PNS) system in the treatment of pain.
The first of these four abstracts—titled, ‘60-day PNS versus standard interventional management for chronic low back pain (LBP): RESET randomised controlled trial (RCT) primary endpoint results’—reports on the effectiveness of PNS compared to standard interventional management for chronic LBP. SPR states that data from this RCT indicate that 60-day percutaneous PNS provide clinically meaningful and statistically superior reductions (≥50%) in pain as well as improvements in function and quality of life (p<0.05) at three months after the start of treatment, with results appearing to be sustained through 12 months post-treatment.
Another abstract titled, ‘Bimodal 60-day PNS significantly reduces shoulder pain: outcomes from a retrospective multicentre chart review’, revealed that 60-day PNS was found to be an effective treatment for chronic shoulder pain, as 75% of patients with available end-of-therapy (EOT) outcome data (n=132/176) reported ≥50% pain relief. These patients had a variety of shoulder pain causes and treatment histories, with patients receiving bimodal PNS stimulation (concurrent motor and sensory stimulation targeting two nerves) producing a significantly higher treatment response rate and mean percentage of pain relief.
An additional abstract titled, ‘Percutaneous PNS relieves persistent postoperative pain and improves function: long-term follow-up from a double-blind RCT’, was delivered at NANS 2025 as well. This study’s goal was to characterise the response to 60-day Sprint PNS compared to sham stimulation (placebo) for postoperative pain following total knee arthroplasty (TKA). This multicentre, randomised, double-blind, placebo-controlled trial has demonstrated that the majority of PNS subjects had enduring pain relief and improved physical function from data collected out to 12 months from the start of 60-day percutaneous PNS treatment.
The fourth and final abstract highlighted by SPR—titled, ‘Durable improvements in headache pain after 60-day PNS: six-month outcomes of a prospective single-arm study’—pertained to the MONARCH study. This study intended to collect prospective data on the safety and efficacy of 60-day PNS targeting the greater occipital nerve and third occipital nerve for the treatment of cervicogenic headache and occipital neuralgia. In this institutional review board (IRB)-approved, multicentre, prospective, single-arm study, 85% of participants (n=17/20) reported ≥50% reductions in pain and/or pain interference at EOT, with 82% (n=14/17) continuing to report ≥50% reductions in pain intensity and/or interference six months following the start of treatment.
SPR’s recent press release states that the most common adverse events for the Sprint PNS system in both clinical studies and real-world data include skin irritation and erythema—but, all four of the aforementioned studies (McCormick et al, Aman et al, Dickerson et al, and Gutierrez et al) reported no study-related serious adverse events.